Epilepsy research
-
Randomized Controlled Trial
Prevalence of epilepsy in the 15 years and older in Benin: a door-to-door nationwide survey.
Estimate the prevalence of epilepsy in the 15 years and older in Benin. ⋯ This nationwide study is the first in West Africa. It provides a low prevalence of epilepsy in Benin compared to previous studies performed in this country and in neighbouring countries. Restricted-area studies are often motivated by the presence of specific risk factors and could overestimate the prevalence, while large-scale studies could underestimate other subtle forms of epilepsy.
-
Randomized Controlled Trial Multicenter Study Comparative Study
A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures.
This study assessed the comparative efficacy of pregabalin for refractory partial seizures. ⋯ Pregabalin was demonstrated to be noninferior to lamotrigine in the treatment of refractory partial seizures. Overall conclusions were complicated by an unusually large and heterogeneous placebo response.
-
Randomized Controlled Trial Multicenter Study
Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
To investigate the efficacy and safety of once-daily eslicarbazepine acetate (ESL) when used as add-on treatment in adults with > or = 4 partial-onset seizures per 4-week despite treatment with 1 to 3 antiepileptic drugs (AEDs). ⋯ Treatment with once-daily eslicarbazepine acetate 800 mg and 1200 mg was more effective than placebo and generally well tolerated in patients with partial-onset seizures refractory to treatment with 1 to 3 concomitant AEDs.
-
Randomized Controlled Trial Meta Analysis Clinical Trial
Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials.
Increases in body weight gain are important, and clinically significant adverse effects of several antiepileptic drugs (AED) including valproate and gabapentin. Weight gain may contribute to medication non-compliance, discontinuation, and importantly, may have secondary medical implications as well. Levetiracetam (LEV) is indicated for adjunctive treatment of partial seizures. The objective of the present evaluation was to examine the effects of LEV treatment on body weight in adult patients. ⋯ We conclude that treatment with LEV at clinically relevant dosages is not associated with significant weight change. LEV would, therefore, appear to be a weight neutral AED.
-
Randomized Controlled Trial Clinical Trial
Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
To evaluate the long-term clinical usefulness of levetiracetam (LEV, Keppra((R))(1)) as add-on therapy in patients with refractory epilepsy. ⋯ LEV offers sustained efficacy in patients with refractory partial seizures, and its long-term tolerability is similar to that seen in the short-term placebo-controlled trials.